 |
N-Methyl-2-[3-[((E)-2-pyridin-2-yl-vinyl)-1H-indazol-6-ylsulfanyl]benzamide |
|---|---|
| Trade Name | Axitinib |
| Orphan Indication | Papillary thyroid cancer |
| USA Market Approval | USA |
| USA Designation Date | 2007-05-04 00:00:00 |
| Sponsor | Pfizer, Inc.;10646 Science Center Drive;San Diego, California, 92121 |
